Pharming Group's Stock Soars 4.8% Midday, Driven by Momentum
At midday this Thursday, November 20, Pharming Group's stock is up by 4.82% at 1.456 euros, having closed the previous day at 1.39 euros. This increase occurs in a favorable stock market environment, with the CAC 40 up by 0.88% at 8,023.66 points. Trading volumes remain moderate with 1.82% of the capital traded during the session.
Investor Focus on Pharming Group Following Key Conference Participation
The Dutch pharmaceutical company is currently benefiting from investor attention following the participation of its CEO, Fabrice Chouraqui, in the Jefferies Global Healthcare Conference held in London from November 17 to 20, with a Q&A session organized on November 19. This media visibility follows the publication of strong quarterly results at the beginning of November. The company had announced a 30% growth in its revenue for the third quarter of 2025, reaching 97.3 million dollars, while its operating profit quadrupled to 15.8 million dollars. From a broader perspective, the stock has shown remarkable performance with a 105.2% increase over the year, significantly outperforming the 10.98% recorded by the CAC 40 over the same period. In the shorter term, the stock has gained 38.93% over three months, confirming a sustained upward dynamic. However, volatility remains high at 23.92 over a month, reflecting the typical fluctuations of biotechnology stocks. The beta of 0.58 indicates moderate sensitivity to market movements, with the stock being less volatile than the benchmark index.
Technical Indicators Present a Mixed Outlook
From a technical standpoint, several indicators suggest a mixed situation. The RSI is at 70, nearing the traditionally set overbought zone at this level, which could signal a potential pause after the recent rise. The stock is currently close to its resistance level at 1.49 euros, which it is trying to surpass during the session. Concurrently, the MACD shows positive signals with a MACD line at 0.05 above the signal line at 0.04, and a positive histogram at 0.02, confirming the bullish momentum in the short term. The moving averages reinforce this constructive trend. The price is above the MM50 at 1.25 euros and the MM200 at 1.16 euros, a technical configuration characteristic of an established bullish trend. The gap between these two moving averages, which is gradually widening from 0.08 euros to 0.10 euros in recent periods, indicates a positive divergence supporting the favorable orientation of the stock. The major support is now at 1.10 euros, providing a safety net in case of a correction.
Company Raises 2025 Annual Forecasts Amid Strong Product Performance
The company has raised its annual 2025 forecasts, now targeting revenue between 365 and 375 million dollars, reflecting management's confidence in the commercial trajectory. This revision is particularly based on the 29% growth in sales of RUCONEST, its flagship treatment for hereditary angioedema, which generated 82.2 million dollars in the third quarter, and on the 35% progression of Joenja, reaching 15.1 million dollars due to a 25% increase in the number of treated patients. The market is also closely watching the expected FDA decision in January 2026 regarding the pediatric extension of leniolisib for children aged 4 to 11 years with APDS syndrome, which could open new growth prospects. In the immediate term, the favorable technical configuration and the positive momentum observed at midday suggest that investors continue to anticipate favorably the upcoming catalysts of the file, even though the proximity of the RSI to the overbought zone calls for caution at current levels.
